Prelude Therapeutics (PRLD) EBITDA Margin (2024 - 2026)

Prelude Therapeutics (PRLD) reported EBITDA Margin of 309.54% for Q1 2026, down 0.63% sequentially from 307.59% in Q4 2025.

Prelude Therapeutics (PRLD) EBITDA Margin (2024 - 2026) Analysis & Trends

Prelude Therapeutics (PRLD) has 3 years of EBITDA Margin data on file, last reported at 309.54% in Q1 2026.

For the quarter ending Q1 2026, EBITDA Margin changed N/A year-over-year to 309.54%; the trailing twelve-month figure through Mar 2026 stood at 503.21% (changed N/A YoY), and the FY2025 full-year result was 861.33%, up 113458.0% from the prior year.
EBITDA Margin eased to 309.54% in Q1 2026, from 307.59% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 307.59% in Q4 2025 to a low of 1145.87% in Q3 2024.
A 3-year average of 584.58% and a median of 314.12% in 2025 frame the typical range for EBITDA Margin.
Peak annual rise in EBITDA Margin reached 83174 bps in 2025, while the deepest fall reached 53819 bps in 2025.
Tracing PRLD's EBITDA Margin over 3 years: stood at 845.78% in 2024, then soared by 64 bps to 307.59% in 2025, then retreated by 1 bps to 309.54% in 2026.
Business Quant data shows PRLD's EBITDA Margin at 309.54% in Q1 2026, 307.59% in Q4 2025, and 314.12% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Prelude Therapeutics	324.30 Mn	179.71 Mn	-	-309.54%

Download Data